Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
| Market Cap | 359.70M+9.5% |
| Revenue (ttm) | 65.26M+0.7% |
| Net Income | -63.23M+31.3% |
| EPS | -2.41+44.3% |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,664 |
| Open | 12.09 |
| Previous Close | 12.17 |
| Day's Range | 12.05 - 12.56 |
| 52-Week Range | 10.20 - 17.15 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 20.00(+61.68%) |
| Earnings Date | Nov 16, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ENTA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENTA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENTA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENTA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENTA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENTA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ENTA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $11.69M |
| IWMiShares Russell 2000 ETF | $9.08M |
| VXFVanguard Extended Market ETF | $4.18M |
| IBBiShares Biotechnology ETF | $2.54M |
| VTWOVanguard Russell 2000 ETF | $2.18M |
| SLYSPDR S&P 600 Small Cap ETF | $1.77M |
Estimated from each fund’s disclosed top holdings × AUM
ENTA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ENTA’s recent data — informational, not investment advice